LivaNova PLC (LIVN)

64.87 +0.54 (+0.84%) At close: 04:00PM EDT

LivaNova PLC

20 Eastbourne Terrace
London W2 6LG
United Kingdom
44 20 3325 0660
https://www.livanova.com

Sector(s): Healthcare
Industry: Medical Devices
Full Time Employees: 3,000

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Damien McDonald	CEO & Director	1.28M	N/A	1965
Mr. Alex Shvartsburg	Chief Financial Officer	445.29k	N/A	1971
Ms. Keyna Pidcock Skeffington	Sr. VP, Gen. Counsel & Corp. Sec.	623.28k	N/A	1963
Mr. Marco Dolci	Pres of Cardiopulmonary Bus. Unit	744.15k	N/A	1962
Deanna Wilke	Director of Corp. Communications	N/A	N/A	N/A
Mr. Matthew Joseph Dodds III	Sr. VP of Corp. Devel.	N/A	N/A	N/A
Ms. Trui Hebbelinck	Chief HR Officer	N/A	N/A	1972
Dr. Bryan D. Olin Ph.D.	Sr. VP & Head of Product Devel. - Neuromodulation	N/A	N/A	1967
Mr. Paul R. Buckman	Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement	N/A	N/A	1956
Mr. Ryan Miller	Sr. VP of Strategy	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.

Corporate Governance

LivaNova PLC’s ISS Governance QualityScore as of May 1, 2022 is 3. The pillar scores are Audit: 3; Board: 1; Shareholder Rights: 4; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.